StemCell Therapy

By Katelyn Earhart

sac-ranger@alamo.edu

The student advocacy center is hosting a free Health and Wellness Event from 9 to 1 p.m. Nov. 2.

File

This event will have free vision screenings provided by The University of the Incarnate Word School of Optometry, with some families able to qualify for free glasses, lenses or eye exams.

Children who participate in this screening will receive a free book.

Essilor, an international optics company, reported Poor vision not only affects a childs eyesight. It can also affect his/her health, school progress, and societal integration. In fact, 80% of what children learn is acquired though visual processing.

The student advocacy center is trying to combat these types of disadvantages by hosting this event.

Along with the vision screening, there will be flu shots available, STD/HIV screenings, dental and financial advising, and health screenings for blood pressure and glucose.

During this time, the Magic Closet will be opening its doors to both the students and their families to receive free clothing and assistance.

For more information, email Robyn Stassen at restassen@alamo.edu or call 210-486-1262.

Go here to see the original:
Free vision screening, flu shots and health advice offered in Advocacy Center - The Ranger

Were not doing enough to protect our sight here are the dos and donts

Bad news for would-be zombies. This week the College of Optometrists is highlighting the dangers of wearing unprescribed novelty contact lenses the kind that change your eye colour or make you look like a member of the undead.

The problem is that lenses bought online or in fancy dress shops wont fit your eye shape and could cause bruises or scratches that can get infected. Every year we see a rise in serious problems, with people buying them from an illegal source and then not wearing them sensibly, says Daniel Hardiman-McCartney, one of the colleges clinical advisers.

Its not only at Halloween. We dont look after our eyes as well as we should particularly given that polls consistently show that we prize our sight

Want to read more?

Subscribe now and get unlimited digital access on web and our smartphone and tablet apps, free for your first month.

See the original post:
Eye health guide: what to look out for, from your diet to makeup - The Times

If youre tired of struggling with poor eyesight, specifically someone who wants to improve their vision, reverse glaucoma, cataract, near-sightedness and wants to stop using glasses, then here is good news.

I have discovered a natural herbal remedy that has helped over 642 Nigerian men, women and children restore eyesight, improve vision and cure severe eye problems within few weeks without using drugs, or eye drops.

You see, I was once in your shoes, I used to battle severe eye problems that made me had blurred vision, dry itchy eyes.

But my eye doctor told me I could only live with it, so my optometrist kept on recommending contact lens (or spectacles) so I could manage it to improve my vision.

But, as time went by the contact lens became ineffective, caused several eye irritations and also negatively affected my self esteem.

3 years later, my eye condition had worsened after several eye exams, I was diagnosed with glaucoma in the right eye.

Again, several solutions like eye drops, pills and surgery was recommended.

Eye surgery which was the best long term treatment was really expensive, and even comes with its own side effects after several months or years.

So, I decided to start using eye drops just so I could manage to see because at this point, I was literally going blind.

You see, the problem with eye drops is that most of them came with serious side effects, so one has to continue changing them until you see the most suitable one.

Sadly, within few months I used over 5 eye drops.

While for over the counter eye drugs, they take almost forever to work and give you perfect eye so you keep on spending and spending on the drugs for several years.

So, I decided to start searching for an alternative solution, something herbal that comes with no side effects and will naturally reverse glaucoma, cataracts, near-sightedness, and other severe eye problems.

But the entire situation changed when I came in contact with an old time friend, Uwem, he used to work in a particular eye clinic in Abuja .

We have been friends since our NYSC days for over 7years till date. Although, it has been a long time we spoke because he relocated to Canada to continue his profession.

We started talking as usual, and he asked me about my eye condition, if it has improved for better.

I explained how I was already tired of looking for solution to the eye problem, and how I have spent lots of money on drugs, supplements, eye drops and glasses, desperately looking for solution but without any improvement, insteadI was almost getting blind instead!

He explained that most people wearing eye glasses suffer from myopia (nearsightedness), glaucoma and cataract.

He later explained that there ispermanent cure for most of the eye problems, and natural remedy that helps treat and reverse glaucoma, cataract, myopia and other severe eye problems.

Most of these cases he has handled in the eye specialist clinic he works with in canada, and his patients improved their eyesight, and they never had to wear glasses or go for expensive eye surgery again.

But sadly, the solution is very rare to find because its imported, specially for Eye clinics in the USA, UK, Canada and some developing African countries as well.

That was when he introduced me to aspecial herbal teathat have been in existence for several years, that help cures severe eye problems, reverse cataract, glaucoma and myopia.

At first, I was shocked and surprised. But he told me the exact plant extracts contained inside the herbal tea, and how they improves overall eyesight health and restores vision.

I quickly pleaded with him to help me send a complete supply of the herbal tea. The next morning, I quickly sent the money to him.

After about a week, the complete supply of the herbal tea was delivered to me.

Immediately, I started it using it as prescribed (serving size of 1 tea bag in morning, and 1 tea bag in the evening).

To my surprise, in less than 2 weeks of using it, it was almost like a miracle cure to my eyesight problem and it helped improve my vision.

My eyes became crystal clear, my vision was never blurry again, and I started to feel that my glaucoma was gone.

To ensure it was really effective,I had to give the same herbal tea to about 2 of my colleagues in a different branch office, and some of my relatives using spectacles just to confirm if it could help them improve their eye health and cure eye problems.

Within 30 days or less of using it, all of them came back to testify that this herbal tea helped them improve their eyesight and cure eye problems like cataracts, glaucoma, near-sightedness, hyperopia, and blurry vision, and they didnt have to continue wearing glasses anymore.

To ensure that this solution really works, I went to my eye doctor, just to be completely sure be about it.

After several eye exams, he confirmed that my eye was much better than before, and that the herbal tea also contained some ingredients that are very rare to find, but are highly effective in improving eyesight naturally.

Without wasting time, let me introduce you to the Herbal Remedy that Has Helped me and over 2,742 Nigerian men and women Improve Eyesight, vision and PROVEN to cure Severe Eye Problems

Eye Restore Tea

Eye Restore Teais a herbal remedy formulated to treat and permanently cure all kinds of eye problems such as glaucoma, myopia, hyperopia, cataracts and lot more

It helps restore your eyesight, promotes eye health and improves vision.

Eye Restore Tea is made up of finely blended plant herbal extractssuch as bilberry extract, chrysanthemum, chinese wolfberry, cassia seed and green tea.

A pack of eye restore tea contains 20 tea bags, which you use daily, morning and evening.

The best part is that the Eye Restore tea is purely herbal, comes without any side effect and curative for the treatment of most eye problems. And within few days of taking this herbal tea, you can start seeing improvement in your vision and eye health.

Eye Restore Tea has the highest standard of approval by International FDA bodies. Its produced in the best, biggest and professional tea manufacturing factory withcertificate of GMP Good Manufacturing Practice, HACCP, Food Production License, QS etc.

So you can be sure that, Eye Restore Tea is Safe, 100% Herbal and Healthy, No Side Effects.

Do you want to dump your glasses, and also put an end to using expensive eye drugs that takes almost forever to work?

Then pay attention to this.

Eye Restore Teais made of herbal extracts, that after several years of research, scientist prove that these herbs help eliminate any form of eye problems, gives a crystal clear eye, improves eye sight and vision naturally.

One of the herbal extracts inside Eye Restore Tea, known asChrysanthemumhave been used for thousands of years by the chinese totreat the eyes, blurring, spots in front of the eyes, diminished vision and dizziness.

According to Chinese traditional medicine, Chrysanthemum is said to be effective at improving eyesight and treating illness associated with the eyes like blurred vision, glaucoma and dizziness.

Another herbs that Eye Restore Tea contains isWolf berry (also known as Goji berries).Wolf berry have been known to improve eyesight and Chinese doctors have for thousands of years studied them for many medicinal treatments.

Wolfberries contains beta carotene (known as the retina food), Vitamin C, and also rich in vitamins B1, B6 and E and other minerals.

Apart from that,wolfberries have high levels of zeaxanthin, lutein, polysaccharides and polyphenolics, which have been shown to improve vision, including the prevention of age-related macular degeneration and diabetic retinopathy.

But whats so special about wolfberries makes manyChinese doctors boast that it greatly improve eyesight?

Wolfberries are used as tonic for the kidney and liver functions. Problems with eyesight, particularly blurred vision, may be due to an imblance in the liver and kidney which is why wolfberries are used as an effective cure.

And once you combine it with other powerful herb extracts like chrysanthemum flower, it helps improve vision and cure disorders such ascataracts, glaucoma, retinopathy as well as macular degeneration.

But thats not all, another powerful ingredients blended inside the Eye Restore Tea areBilberry and Cassia seed.

Bilberry is rich in antioxidant compounds known as anthocyanins. Bilberry is known to improve the health of the eyes, improve night vision and protect against eye conditions like age-related macular degeneration, cataracts, and glaucoma.

Believe me, these are very rare,highly effective herbsthat will help treat and cure any type of eye problem such as Near-sightedness (Myopia) , Far-sightedness (Hyperopia), Glaucoma, Cataract, Eye Strain, Macular Degeneration, Astigmatism, Presbyopia (Old-Age Sight), Diabetic Retinopathy etc.

Heres how this special herbal tea works

When you order for the Eye Restore Tea, each pack contains 20 tea bags. Put 1 tea bag in the cup, add boiled water, you can add honey or lemon (depending on your taste). Drink the tea in the morning when you wake up, and in the night before bed.

Within 3 weeks or less, I can guarantee that it will cure whatever eyesight problem you are experiecing at the moment. It will improve and perfect your eyesight, you will be able to read better anytime of the day. It will help you see comfortably without your glasses.

THATS how powerful it is.

Right now, my eyes are crystal clear, no more blurry vision, I see clearly without my eye glasses, glaucoma has gone, and no more cataracts.

And after this worked for me, Ive gone to share this amazing eye restore secret with almost everyone (family, friends and collegues) that I know that uses spectacles, or have severe eye problems for many years.

And once they started using Eye Restore Tea, they experienced similar results, their joy knew no bounds and they were able to dump their glasses, save money on expensive drugs and eye drops.

While it has also helped them to have a much improved vision, eyesight and totally natural cure to glaucoma, cataracts, myopia, hyperopia, eyestrain and other eye problems.

And to Prove It, Here Are What People Who Have Used theEye Restore Tea Are Saying About it, and How TheyveSeen Great Results Using it

For over 3 years of having glaucoma in my right eye, Ive been eye drops that my eye doctors prescribed. After using it for a long time, I noticed that the eye was becoming useless, and I only had my left eye for all purpose.Until I came accross Eye restore tea, I decided to use it instead. Within few weeks, I began to see better. I went to the Eye center, and after the examination doctor say that my eye has improved and the IOP has dropped.Thanks so much for this wonderful solution that saved my eyes

James Gwarimpa, Abuja=================

I suffered from Glaucoma for about 2 years now, and I had to use eye drops to control it. But the eye drops have serious side effects that made me uncomfortable so I had to keep changing them and used 5 types of eye drop.Luckily, a friend introduced me to Eye restore tea, so I decided to give it a trial. My vision now have improved up to the extent that I no longer need spectacles or any eye drop again.

Mrs. Tolulope Ketu, Lagos===============

Immediately after my cataract sugery, I used to have a foggy or cloudy vision and colors are not vivid as they were. I got corrective sight vision lens, and after many months I still get this blurry vision sometimes which is frustrating.

My wife helped me order for the Eye Restore tea, and I decided to use it, within 6weeks, my eyesight is clear and has corrected itself with time. Ive gone on to recommend this for my elder brother with similar eye problems. Thanks so much for this miracle tea

Mr. Victor Onitsha, Anambra

============After seeing an opthalmologist for an eye exam, it was revealed an eye pressure of 25 in both eyes, and my right eyes looked suspicious for glaucoma. I continued using eye drops.

I stumbled upon your eye restore tea product, and decided to go for it. Within few weeks of using the tea, am seeing obvious changes, and finally stopped using eye drops. i will keep you updated on my progress, really appreciate this!

Olawale warri, Delta

Truth is, I could load more and more testimonials from these people who have used the Eye Restore tea but it will only be saying the same thing this product works like crazy!

As you have seen, these people were once like you suffering from similar eye conditions that were a threat to their vision, but they took action got the Eye Restore tea and cured severe eye problems.

As we speak lots of people are raving about this natural miracle eye treatment solution. I wonder what happens when people begin to post experiences and testimonials on social media (Facebook, Instagram, Twitter etc.)

Customers will continue telling friends, and the news keeps on spreading like wildfire.

By word of mouth, theres so much huge demand, supplies are going off the shelf fast even my colleagues and inner circle friends picked up 143 packs of the Eye Restore Herbal tea.

So, there are just 257 packs remaining.

The miracle eye treatment solution is spreading like wildfire and demand is so heavy much of the stocks are running out fast.

Right now, thousand of people are on this website and stocks are extremely limited.

We have no idea when the next stocks will arrive, so get your supplies now while you can.

The best part is, you can get it at an affordable discount price when you place order right away.

I cannot assure you will get it at the same discount price if you procrastinate.

SO WHATS IT COST?

See the original post here:
How 63-year-old Benin grandpa discovered herbal remedy that improves eyesight, treats glaucoma and cataracts without surgery or eyedrops (Sponsored) -...

The summer months may be over, but Israelis and Israeli visitors often head to the beach year-round to soak up the sun, cool off in the Mediterranean, meet friends, or unwind after a long day (or week) away from smartphones and social media.

Time at the beach inevitably comes with risks and in some situations, even the best-trained lifeguards may not be able to help.

According the World Health Organization (WHO), drowning is the third leading cause of unintentional injury death worldwide, accounting for seven percent of all injury-related deaths. It is the leading cause of death in children between the ages of one and four and the second leading cause of death in children between the ages of five and nine. A WHO Global Report says some 372,000 people drown every year.

SEE ALSO: Magen David Adom Inaugurates Sea-Bulance For Emergency Water Rescue

While the risk of drowning can be reduced when lifeguards are in the vicinity, those lifeguards can only cover a certain expanse of beach at a time. Also, they need breaks. And they can rely heavily on binoculars and their own vision only for so long eyesight (and stamina) can certainly falter after hours in the full sun.

An Israeli startup leveraging computer vision technology wants to help. Founded in 2018,Sightbit says it can prevent drowning by alerting lifeguards when swimmers are in danger.

Through the use of a system of beach cameras that utilize the tech, lifeguards get a panoramic view of the water, the beach, and the swimmers, which allows the guards to make rapid rescues or prevent dangerous situations from escalating. The camera footage is displayed on a screen, which is monitored by lifeguards and beach staff.

Behind the scenes, Sightbit algorithms analyze the footage in real-time. When the system detects a threat such as a rip current or a child alone in the water it displays warnings on the screen or sounds alarms.

The software allows lifeguard to track more swimmers and keep them safer, the company says. Sightbit also offers risk analytics which provides data about locations where guards are most needed.

The camera footage is sent to a processing unit, which may be on-site, or on the cloud, where the companys software analyzes visuals on an individual feed. The camera projects real-time images on a screen, which can be monitored by beach staff, or lifeguards.

The system also provides real-time data on rip currents and other hazards.

We have developed a tool that beaches can use as they see fit, Minna Jacobson, the companys co-founder and marketing director, tells NoCamels, It will change the way beaches operate today.

No lifeguard can monitor all swimmers and hazards simultaneously, she explains. The Sightbit system can be customized so that the user gets to decide how much of the beach can be tracked at once.

Jacobson says the product provides drowning alerts based on the users preference. If the lifeguard wants to know when a person is in deep water or when a child is going in, the system can be customized to do so. There are also visual alerts including lines to mark boundaries or hazardous areas or a red flashing box to track a specific person.

The Sightbit team believes its system can shake up the world of ocean rescue. Were not just building a product that beeps at lifeguards. We are revolutionizing ocean rescue, Jacobson tells NoCamels.

The system, currently in its research and development phase, is already highly accurate, the startup says. In a year or two, the company expects to be many times more effective than lifeguards at identifying drowning threats or other risks to swimmers, Jacobson says.

Not only will the system help save lives, it will also save money, Sightbit claims. With some $11 billion spent annually on beach management in the US and another $3.8 billion in beach equipment according to Sightbits research, the startup says it can save authorities approximately $2 billion in labor costs.

The system will allow beaches to save money by allowing them to hire fewer guards or allow beaches to guard more shoreline (many beaches would like to guard larger sections of shoreline but they cant afford to hire additional guards, which are very expensive), Jacobson explains.

She also says Sightbit has few competitors as there are no other AI-powered lifeguard systems for beaches are currently in place, according to the research. There are other solutions, but were created for pool systems, not the beach.

The social impact of Sightbit was a big draw for me, Jacobson says. Its a project that really contributes social value.

Companies and institutions have begun to see the potential of Sightbits innovative system. Cactus Capital, the first student-run university venture capital firm in Israel and a venture arm of Ben-Gurion University of the Negev (BGU) partnered with the company to provide an initial round of funding as well as a network of resources.

Sightbit is also part of the 11 participating startups that make up the second cohort of Yeshiva Universitys Innovation Lab.

In order to understand what the system needed to be at the top of its game, the four-person team that founded Sightbit, which includes Jacobson, CEO Netanel Eliav, CTO Jenia Golbstein, and Operations Director Adam Bismut, interviewed dozens of lifeguards across North Carolina, California, Maryland and New York.

SEE ALSO: How Israel Became An Unlikely Shark Hub, According To A Marine Ecology Expert

The team is also entering its first pilot program with the coastal Israeli city of Ashkelon, by implementing its system on several beaches in the area including the central Bar Kochba beach.

The pilot allows us to test our algorithms in real beach conditions, Jacobson says. Right now, we are focusing on improving our core functions, she says. A machine knows better what constitutes a threat.

Read this article:
Israeli Drowning Prevention Startup Sightbit Says Its Tech Can Revolutionize Beach Rescue | Health News - NoCamels - Israeli Innovation News

ISLAMABAD, Oct 23 (APP):Minister for Federal Education and Professional Training Shafqat Mahmood Wednesday distributed free glasses among 168 students of Islamabad Model College for Girls (IMCG) G/6-1, identified with weak eye sight.

The glasses were distributed under the ICT School-Based Health Initiative, School Eye Health Screening in a vision glasses distribution ceremony organized by a private organization in collaboration with Federal Directorate of Education (FDE) and Ministry of Federal Education and Professional Training.

Under the first phase of initiative, the eye screening of around 200,000 students of the 423 schools, colleges of the Islamabad Capital Territory (ICT) would be checked.

Initially, the eye screening test was held in two public sector schools out of which around 168 students were identified with weak eye sight.

Addressing the ceremony, the minister said that the project has been started by the Sight Saver an NGO on my personal request. He commended the efforts of Country Director Sight Saver Syeda Munaza Gilani for her cooperation in completing the project. He said the expenses of the project were totally given by the Sight Saver.

Weak Eye sight, Shafqat said, was affecting the study of children. He said the initiative would be completed in next two years.

Earlier in her address, Country Director Syeda Munaza Gilani said that this programme has been launched on urgently basis with the personal interest of the education minister.She lauded the role of FDE team for supporting the programme. She said the aim of this programme was to create awareness about various eye sight diseases among the students.

She informed that around 2.2 billion people globally were facing the eye related diseases. According to a survey conducted in Pakistan, she said, around 5.3 percent people were facing weak eye sight issues, adding most of them are girls.

This programme was working in many cities of Pakistan under which more than 70 thousand children had been provided glasses, she said and added, the teachers had also been provided basic training so that they could identify those children having weak eye sight.

Read the rest here:
Shafqat Mahmood distributes glasses among 168 students with weak eye sight - Associated Press of Pakistan

The Overton Park, just off of the downtown district, was jam-packed with colorful people and their amazing automobiles on Saturday. It was a welcome sight that hadnt been seen for quite some time.

The Moapa Valley Car Show has been going on consecutively for 20 years now. It is put on each year by the Moapa Valley Chamber of Commerce with the stated purpose of bringing visitors and business to our sleepy little downtown area. Unfortunately, the past several years have been somewhat bleak on that score. A shortage of volunteer involvement and a lack of adequate marketing have resulted in a trend of diminishing attendance at the event. The people and cars just havent come. By last year, the event seemed to be barely holding on to life with less than 20 cars exhibited. Many folks in town feared that it might be the last we would see of a car show that, in years past had brought as many as 140-some-odd vehicle entries.

But this year the Moapa Valley Car show received a shot of new life! Vanette Christensen, owner of Xtreme Stitch in Overton, was elected President of the Chamber of Commerce with a commitment to do all she could to bring this Car Show back to its former glory. On Saturday, after a year of hard work, she made good on that commitment.

It was no small feat. A successful Car Show isnt just thrown together on a couple weeks notice. It is a unique event aimed at true aficionadoes who deeply appreciate the real thing,but can detect a lackluster half-way effort immediately when they see it. To put on a successful show requires a fellow aficionado who understands the Car Show subculture; what these guys like, where they are and what they expect.

For that, Vanette didnt have to go far. She tapped her husband Gary Christensen to help. Gary started making contacts early in the year. He put out a search for all the movers and shakers in the Car Show crowd throughout the region. Then he spent the past few months going to where these foks gather and speaking to them in their language. Every weekend has found Gary at a different Car Show in the southwestern U.S., handing out flyers, talking to car club leaders and promoting the Overton show everywhere he went. It took countless hours of pounding the pavement. But it paid off.

Vanette also had the help of local couple Lois and Cal Hall, owners of Cals Auto Repair. Lois also serves on the Chamber Board and was fully engaged this year in helping to organize the show.

But to pull off the show and make it a success, the two couples needed help. They found it in a diligent group of Chamber members and others who showed up on event day to help manage all of the details. The sum of all of these efforts yielded a great triumph for the show.

On Saturday, the Car Show achieved most of Vanettes lofty goals. There were about a hundred entries on the grass of the park. And the crowds came from all over to see them. Downtown Overton was bustling and local businesses were busy. It was just like the good ol days.

All of these efforts were successful in bringing the Car Show back to life. And with it came a solid day of commerce for downtown Overton. Customers left their homes and came downtown; including both local folks and visitors from further away. Generating that kind of commerce for local businesses is one of the most important functions of a successful Chamber. And it was gratifying to see that function fulfilled.

Kudos go especially to the Christensens. Their vision, leadership, passion, tenacity and unrelenting legwork have saved the Moapa Valley Car Show for another year from passing into memory.

Of course, the small army of Chamber member volunteers are also worthy of praise. Without their involvement, it would not have been successful. When community events seem to flounder or fail, it is always easy for folks to cluck their tongues, point fingers and assign blame to others for what should have been done better. But there was none of that with these folks. With an eye forward, these volunteers responded to the call to help and were instrumental in turning things around.

Now there is already talk of expanding the Car Show next year. Vanette has a vision of a two-day event that would bring cars for multiple activities highlighting various parts of town. She hopes that someday soon the event might even burst the seams of the Overton Park and move to the Logandale Fairgrounds.

No doubt, she has the momentum, the vision and the drive to see it done. If she can just continue to get the support from the community and its volunteers, amazing things could happen. We look forward to a growing, thriving car show event for years to come. Long live the Moapa Valley Car Show!

Read the original:
EDITORIAL: Vision and involvement revives Car Show - mvprogress

The involuntary eye movement that we noticed with Ollie is called nystagmus and is typical of this disorder, further affecting the vision. (Some call it poetically dancing eyes.) The precise impact on eyesight, though, is complex to define; it varies greatly among people even when they have similar melatonin levels.

Curiously, one of the first things our diagnostician chose to tell us to explain albinism was your son wont be able to drive. I looked at my fairy-fair baby, struggling to imagine him holding a steering wheel, struggling to keep the contents of my stomach to myself

More recently, Ive actually met several people with albinism who drive. But at the time, shell-shocked and unable to extract any hopeful information from our doctor who also told us categorically that glasses dont help I merely retreated home to grieve.

For the following few months, I woke up every morning with a lump in my throat. I carried my tiny son around strapped to my chest with my own vision blurry from tears and lack of sleep, envisioning his devastating future.

My baby trapped in the darkness, bored and lonely; my future toddler stumbling around the house and falling, and falling. I had no idea what to expect.

The internet offered a mostly vague, or contradictory, information. I read that its normal for babies with albinism to see very little, but later theyll be able to see more. How much more? How much later?

Then something changed. The change was called Beth. A white-haired ball of energy, a Vision Australia worker with no medical training but zillions of years of experience, she walked into our house and sat down on the carpet near Ollie.

Beth smiled at him even if he couldnt see it, and sang to him until he smiled. Then she looked up into my wet eyes and said, Hell be fine. Just like that.

Not worried about formal protocols or giving false hopes. Hell be fine

Soon after, Beth arranged for us to meet our future some older children with albinism. None of them stumbled in the dark, although some needed walking sticks, and many rode bikes.

On Beths advice, we also joined the Albinism Fellowship of Australia and attended their conference, where we also met our more distant future adults with albinism who were scientists, musicians, teachers, doctors.

The more people I met, the more I watched my baby who was now crawling all around the house (not stumbling), the looser the lump in my throat became. We bought Ollie his first glasses orange ones, with teddy bears when he was two. They do help him see. (They also help him fancy himself as Harry Potter.)

Four years since that diagnosis, and I now know my greatest fears related to the physical side of Ollies disability havent materialised. He cant see the pictures shown during storytime in his kinder, nor can he see much in the theatre even if we sit close to the stage, and he loses us easily in public places.

Mia Freedman speaks to Vanessa Cranfield on No Filter, about what its like parenting a child with a disability. Post continues below.

But then, most mornings he wakes up with a huge smile, terribly pleased with this complex world.

He rides his scooter with gusto and doesnt shy around playground climbing equipment, even if it presents him with more challenges than the other kids. He began reading and writing before he was four, which is also when he performed his first piano concert. He makes friends easily.

Continue reading here:
'He will never be able to drive.' What it's really like parenting a child with albinism. - Mamamia

PITTSBURGH, Oct. 23, 2019 /PRNewswire/ -- While major drug companies reached a $260 million settlement to avert a federal opioid trial this week, the crisis continues to impact Americans. Researchers at Duquesne University think they have some answers.

Here's How We Can End the Opioid Crisiswill feature brief presentations from members of Duquesne's Chronic Pain Research Consortium, including:

The 45-minute session will begin at 9:30 a.m. on Thursday, October 24. To view the presentation live, click here.

The session is part of Duquesne's Integrative Health Summit, which highlights the university's growing momentum in health sciences education and research. Other sessions will focus on new treatments for deadly diseases; children and family health issues, including the anti-vaccine movement; how integrative techniques help serve marginalized populations, including sexual assault victims and those dealing with violence-related trauma; and the role of the arts in medicine.

Earlier this year, Duquesne announced that it's creating a College of Osteopathic Medicine to help meet a looming physician shortage in the U.S.

Duquesne UniversityFounded in 1878, Duquesne is consistently ranked among the nation's top Catholic universities for its award-winning faculty and tradition of academic excellence. Duquesne, a campus of nearly 9,500 graduate and undergraduate students, has been nationally recognized for its academic programs, community service and commitment to sustainability. Follow Duquesne University on Facebook, Twitter and Instagram.www.duq.edu

Excerpt from:
Researchers Explore How to End the Opioid Crisis at Web Event Tomorrow - Bradford Era

Report Scope: The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries.

New York, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell and Regenerative Therapy Market" - https://www.reportlinker.com/p05791357/?utm_source=GNW The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography.Based on product the market is segmented into therapeutic products, cell banking, tools and reagents.

The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes: - 28 data tables - An overview of global markets for stem cell and regenerative medicines - Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 - Details of historic background and description of embryonic and adult stem cells - Information on stem cell banking and stem cell research - A look at the growing research & development activities in regenerative medicine - Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals - Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018.The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024.

Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018.The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period.

The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications.New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future.

The biopharmaceutical companies are investing significantly in cell-based therapeutics.The government organizations are funding research and development activities related to stem cell research.

These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments.The market is impacted through adoption of stem cell therapy.

The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.Read the full report: https://www.reportlinker.com/p05791357/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

More:
Global Stem Cell and Regenerative Therapy Market - Yahoo Finance

NEW YORK, Oct. 21, 2019 /PRNewswire/ --

Regenerative Medicine Market Size, Share & Trends Analysis By Product (Primary Cell-based, Stem & Progenitor Cell-based), By Therapeutic Category (Dermatology, Oncology) And Segment Forecasts, 2019 - 2025

Read the full report: https://www.reportlinker.com/p05807250/?utm_source=PRN

The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period. Regenerative medicines are expected to have a significant impact in healthcare to treat specific indications and chronic conditions. Therefore, high prevalence of cancer, neurodegenerative, orthopedic, and other aging-associated disorders coupled with increasing global geriatric population is driving the market growth. Moreover, rising prevalence of inheritable genetic diseases is anticipated to fuel the demand in the field of biotechnology field.

Market players are engaged in implementing novel protocols for the release of novel therapeutics. For instance, in July 2018, Convelo Therapeutics launched regenerative medicines for the treatment of various neurological diseases, such as multiple sclerosis.Agreements models initiated by the companies coupled with commercialization in emerging countries fuels the growth. For instance, in March 2018, Hitachi Chemical signed an agreement with the Daiichi Sankyo and SanBio Group to conduct clinical manufacturing of regenerative medicines developed by respective companies for Japanese and U.S. markets.

Regenerative medicine is anticipated to witness great attention in healthcare sector due to its wide range of applications and significant advancements tissue engineering, stem cells, gene therapy, drug discovery, and nanotechnology. For example, 3D printing is preferred over scaffold with stem cells to restore structure and functional characteristics of biological specimens.

Dermatology is estimated to hold the largest market share in terms of revenue in 2018, owing to the availability of various products and their application in simple and chronic wound healing. Oncology therapeutic category on the other hand, is projected to expand at the fastest CAGR during the forecast period owing to the presence of strong pipeline of regenerative medicines for cancer treatment.

North America held the largest regenerative medicine market share in terms of revenue in 2018 and is projected to continue its dominance in near future. A significant number of universities and research organizations investigating various stem cell-based approaches for regenerative apposition in U.S. is anticipated to propel the growth.

Further key findings from the report suggest: Therapeutics emerged dominant among product segments in 2018 due to high usage of primary cell-based therapies along with advances in stem cell and progenitor cell therapies Implementation of primary cell-based therapies in dermatological, musculoskeletal, and dental application results in highest share of this segment Stem cell and progenitor cell-based therapies are anticipated to witness rapid growth due to high investments in stem cell research and increasing number of stem cell banks With rise in R&D and clinical trials, key players are offering consulting services leading to lucrative growth of the services segment Asia Pacific is projected to witness the fastest CAGR during the forecast period due to rapid adoption of cell-based approaches in healthcare and emergence of key players Key players operating in the regenerative medicine market including AstraZeneca; F Hoffmann-La Roche Ltd.; Pfizer Inc.; Merck & Co., Inc.; Integra LifeSciences Corporation; and Eli Lilly and Company

Read the full report: https://www.reportlinker.com/p05807250/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read more:
The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period -...

MIAMI - October 24, 2019 - ( Newswire.com )

The AASCP has recently created guidelines thatare current safety recommendations given to physicians who are using biologics in their medical practice. A highly anticipated and sought after Safety StandardsPanel session, hosted by AASCP on Nov. 2, 2019, will be moderated by The Alliance for Cell Therapy Now,with President Ms. Janet Marchbrody.The sessions normally are closed to the public but this particular SafetyStandard Panel discussion will be open to the public, covering the growing safety concerns of the industry.

Alliance for Cell Therapy Now is a coalition of organizations representing patients, health care providers and the academic and scientific community, who are working together to advance safe and effective regenerative cell therapies. The mission is to advance the development, manufacturing and delivery of safe and effective regenerative cell therapies through policy development, consensus and advocacy. Alliance for Cell Therapy Now is bringing together experts and stakeholders to gain consensus on and advocate for policies that will advance the science and the field, including those focused on promoting clinical research, assuring the adoption of consensus standards to promote safety and quality, building capacity and expertise within the workforce, and establishing a national outcomes database to advance the science, promote improvements in quality and safety, and inform regulatory, paymentand patient decision-making.

Alliance for Cell Therapy Now is guided by an Advisory Board comprised of leaders in the scientific, academicand patient communities; Ms. Janet M. Marchibroda President, Alliance for Cell Therapy Now Fellow, Bipartisan Policy Center Senior Vice President, Health Policy, Bockorny Group, has agreed to join theAASCP as a moderator for their SafetyPanelat The Hyatt Regency in Miami. This particular coveted safetypanel session will be open to the public and broadcast live on YouTube at 3:00 p.m. on Nov. 2, 2019.

According to AASCP, if you are using biologics in your practice, whether you are using SVF, PRP, bone marrow, UCB, amniotic products,exosomes,xenografts, or peptides, there are key considerations to take into account to achieve the best safety for your patients. The AASCP also recommends communication with the Chief Scientific Officer from the laboratory you work with.AASCP advises that just talking to a sales agent is not sufficient enough when determining the quality of products for your patients. Sales agents typically do not have a medical or scientific background.

The spokesman for the AASCP, Dr. AJFarshchian,said earlier: The American Academy of Stem Cell Physicians is a group of physicians, scientists and researchers who collectively represent the most authoritativenon-federal group advocating for guidelines and education on stem cell therapy and regenerative medicine. AASCP members are experts within all fields of stem cell therapy from: SVF, BM, UCB, Exosomes, Peptides, Xenografts, Allografts and Amniotic Fluids and are considered the most experienced leaders for proper advocacy in the field. The AASCP is involved directly with other authorities within the field and seeks only to bring knowledge and awareness for the ever growing regenerative medicine industry.My hope is that the SafetyPanel discussion on Nov.2, 2019, is to help get rid of the bad actors that are damaging the field for everyone.

AASCP is hosting their medical conference in Miami on Nov. 1-3 , 2019. Sessions are normally closed to the public and, therefore, require registration. The conference is taking place at the downtown MiamiHyatt Regency, located at 400 SE 2nd Ave, Miami, FL 33131.Becauseof limited seating, we encourage everyone to please RSVP ataascp.net andto register.

The American Academy of Stem Cell Physicians (AASCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatmentand prevention of disease related to or occurring within the human body. Secondarily, the AASCP aims to serve as an educational resource for physicians, scientistsand the public in diseases that can be caused by physiological dysfunction that areameliorableto medical treatment.

For further information, please contact Marie Barbaat AASCP 305-891-4686 and you can also visit us at http://www.aascp.net.

Related Links AASCP Safety guidelinesAASCP website / registration

Press Release Service by Newswire.com

Original Source: American Academy of Stem Cell Physicians Announced Today That Their Safety Panel Session is Open and Free to the Public

Follow this link:
American Academy of Stem Cell Physicians Announced Today That Their Safety Panel Session is Open and Free to the Public - Valdosta Daily Times

Nerve Repair And Regeneration Market Size, Share & Trends Analysis Report By Surgery (Nerve Grafting, Neurorrhaphy), By Product (Biomaterials Neurostimulation & Neuromodulation Device), And Segment Forecasts, 2019 - 2026

New York, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Nerve Repair And Regeneration Market Size, Share & Trends Analysis Report By Surgery, By Product And Segment Forecasts, 2019 - 2026" - https://www.reportlinker.com/p05807210/?utm_source=GNW

The global nerve repair and regeneration market size is expected to reach USD 17.8 billion by 2026 registering a CAGR of 10.7%. Demand for neurological disorder therapies owing to increasing incidence and rising awareness about the same will drive the market. Moreover, government funding and reimbursement policies and uninterrupted technological advances are also projected to help boost the market growth.

In January 2016, the EU Horizon 2020 program funded a research project Autostem, launched by the NUI Galways Regenerative Medicine Institute (REMEDI), costing about USD 6.73 million. This project was to develop a robotic stem cell production factory, having an edge over the old traditional techniques. This technique offers prospects of new therapies for a range of diseases, such as cancers, diabetes, and arthritis. Increased R&D and investments by key companies in emerging countries are also driving the market growth. In July 2018, the Stem Cells Australia (SCA) received USD 3 million for stem cell research from the Medical Research Future Fund (MRFF).

In addition, government and private funded organizations are conducting clinical trials to develop a safe and effective therapy for different neurological disorders, such as Stem Cells in Umbilical Blood Infusion for Cerebral Palsy (Phase II) and usage of Polyethylene glycol (PEG) drug (Phase I) to promote axonal fusion technique to repair peripheral nerve injuries in humans.

Furthermore, in October 2017, Stryker Corporation acquired VEXIM, a France-based medical device company.VEXIMs portfolio is complementary to Strykers Interventional Spine (IVS) portfolio.

With this acquisition, Stryker will strengthen its distribution channels in Eastern Europe, Middle East, Asia, and Latin America. In January 2018, Boston Scientific Corporation received U.S. FDA approval for the first and only Spectra WaveWriter spinal cord stimulator system. This system is used for paresthesia-based therapy.

Further key findings from the study suggest: In 2018, neuromodulation and neurostimulation devices segment led the market due to increased cases of Central Nervous System (CNS) disorders and awareness about mental disorders and available treatments Biomaterials is anticipated to expand at the fastest CAGR during the forecast period due to technological advancements and development of biodegradable polymers that can help enhance spinal stabilization, healing of fractures, and reduce hospitalization North America led the market in 2018 owing to technological advancements and advent of new devices. Government initiatives and funding and increased cases of injured CNS, such as injuries to the spinal cord and brain, were some of the major reasons responsible for the regions growth Asia Pacific is expected to be the fastest-growing market during the forecast period. Growing geriatric population, technological advancements, and many unmet medical needs are some of the factors driving the regions growth In February 2016, Indian scientists working for Revita Life Sciences were approved to conduct clinical trials in 20 clinically dead patients to bring specific parts of their CNS back to life Combination of therapies including cocktail of peptides, nerve stimulation techniques, injecting the brain with stem cells and other techniques that were successful in bringing patients out of coma were to be used Existing medical devices were combined with regenerative biological medicines with an objective to achieve such a complex initiative Some of the key companies include Boston Scientific, Inc.; Stryker Corporation; St. Jude Medical, Inc.; Medtronic plc.; Baxter International, Inc.; AxoGen, Inc.; Polyganics B.V.; Integra; Cyberonics, Inc.; and Lifesciences CorporationRead the full report: https://www.reportlinker.com/p05807210/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Follow this link:
The global nerve repair and regeneration market size is expected to reach USD 17.8 billion by 2026 registering a CAGR of 10.7% - Yahoo Finance

NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced, Chaim Lebovits, President and CEO, will serve as a Keynote Speaker at Cell Series UK.Cell Series UK, will be held October 29-30, 2019, at London Novotel West, London, UK. The Conference, organized by Oxford Global, is one of the foremost events in Europe focused on regenerative medicine and cellular innovation.

Ralph Kern MD, MHSc, Chief Operating and Chief Medical Officer of Brainstorm, who will also participate at Cell Series UK stated, We are very pleased to have Chaim Lebovits presenting at this prestigious conference where global leaders in stem cell and regenerative medicine will have the opportunity to learn more about NurOwn and the critical research being conducted by the Company. Mr. Lebovits Keynote Address, Stem Cell Therapeutic Approaches For ALS, will be presented to leading members of the scientific and business community including potential partners and investors.

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

AboutBrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website.

Safe-Harbor Statements Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PR Phone: +1.646.677.1839sean.leous@icrinc.com

See the original post here:
BrainStorm Cell Therapeutics' President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019 - GlobeNewswire

Thought regenerating tissue was just for salamanders? It turns out that humans can regenerate certain tissues faster than others too.

A study authored by Duke researchers found that humans have the ability to regenerate cartilage in certain joints, though some are faster than others. These findings could potentially lead to new treatments for osteoarthritis, one of the worlds most common diseases.

The study, which included research going back more than a decade, outlined the discovery of an age gradient for different types of cartilage in humans. The researchers examined protein modifications and discovered that ankle cartilage had a higher rate of production than cartilage in the knees or hips.

That was a big surprise because most people think that all cartilage is the samesame proteins, same everything, said Professor of Medicine Virginia Kraus, the senior author of the study. We expected to be able to see a different turnover of different proteins, but the fact that it was changing by location, that was really surprising.

To contextualize these findings, Kraus and Ming-Feng Hsueh, a medical instructor in the department of orthopedic surgery and the studys lead author, went back millions of years to the evolution of a small lizard-like amphibian: the salamander. Salamanders are noteworthy in the animal kingdom due to their ability to completely regenerate lost limbsan ability that is shared by only a few other animals, such as zebrafish.

A study published in 2016 found that salamanders, zebrafish and another limb-regenerating type of freshwater fishall of which were separated by millions of years of evolutionhad essentially the same mechanisms for joint repair.

These mechanisms worked more effectively in repairing the parts of limbs that were closer to the torso compared to those that were farther away. This was a direct parallel to humans seemingly being able to repair cartilage in ankles much faster and more easily than in hips.

To Kraus and Hsueh, this signified that these regeneration mechanisms could be the same ones present in humans. This hypothesis was further bolstered by reports of children who could regenerate the distal parts of their fingertips. However, researchers dont know why or how this ability is turned off.

Limb regeneration is highly complex, Kraus said. Just looking back at [salamanders and zebrafish] with a fresh eye and trying to say, What is it about that process that we either share or we dont share? is how maybe we might be able to gain insights into what is lacking [in humans].

In fact, they found that this innate regenerative capability likely does exist in people.

From our study, we think that humans still have the ability [to regenerate limbs] or at least repair them to some level, Hsueh said. We think that the key factors to doing this are either missing or insufficient in humans. Our strategy for the future is to try to find the key factors that humans do not have enough of.

The factors that regulate the process of joint repair are known as microRNA. Hsueh explained that the answer to increasing repairability in joints afflicted by osteoarthritis is locating the microRNA that is in high abundance in ankles and increasing its level in other joints, such as the hip.

Signup for our editorially curated, weekly newsletter. Cancel at any time.

However, beyond increasing the amount of beneficial microRNA, Kraus and Hseuh also noted that it is necessary to identify and turn off bad microRNA, which may inhibit collagen production and thus aggravate osteoarthritis. Just like every other system in the body, joint repair is about balance.

This study may lead to new ways of treating osteoarthritis, which occurs when the cartilage at the ends of bones wears down. It can cause severe joint pain, swelling and stiffness, and currently affects an estimated 27 million Americans as of 2018.

Kraus said that unlike rheumatoid arthritis, which has treatments to prevent the disease as well as put it into remission, there are currently no existing effective treatments for osteoarthritis.

Contrary to popular belief, osteoarthritis isnt just a geriatric disease.

We know that 50% of people who get an anterior cruciate ligament tear will get osteoarthritis at a young age. So any time I watch the Duke basketball team and somebody goes down, Im like this is terrible, Kraus said. They have a one in two chance of developing osteoarthritis in just a few years.

Kraus and Hsuehs short-term goal is to help boost cartilage repair in patients with osteoarthritis, sports injuries and amputated limbs. In the long term, they hope to eradicate osteoarthritis entirely.

I think [in 50 years] well be in an enviable position in the way rheumatoid arthritis is thought of now, Kraus said. I think therell be early identification, well have really robust treatments, [and] joint replacements will be rare. I think well treat joint injuries very seriously the way heart attacks are treatedimmediately, with something really effective.

The researchers said funding is the biggest problem going forward. Most of the support for the study came from the National Institutes of Health, but according to Hsueh, who has been working on the study since he was a graduate student, obtaining grants is constantly an uphill battle.

Its breaking new ground and its really hard to get old thinking to change, Kraus said. Its a hard sell.

Kraus and Hsueh believe there is much work that can be done outside the field of rheumatology and orthopedics to contribute to these advancements, including collaborating with developmental scientists, experts in salamanders and specialists in regenerative medicine.

By putting the right brains together so that theres more crosstalk, that would really facilitate the advancements, Kraus said. Thats the future.

Originally posted here:
Regeneration race: Cartilage regrows faster in some joints than others - Duke Chronicle

The build-out is estimated at $9.5M.

United Therapeutics received a building permit Tuesday for a $9.5M build-out of its cell therapy facility on the second floor of Mayo Clinics Discovery and Innovation Building.

The 21,843-square-foot space will house an automated stem cell manufacturing site, which is one of the first of its kind in the country. The Whiting-Turner Contracting Co. is the project contractor.

The technology, approved by the FDA in 2018, allows the Mayo Clinic Center for Regenerative Medicine to produce cells from the bone marrow of a stem cell donor in large enough quantities to be used as treatments in clinical trials. It allows for the treatment of multiple patients at the same time.

Construction began in 2017 on the $32.4M building at 14221 Kendall Hench Drive. It held a grand opening in August.

The first floor houses three ex-vivo lung perfusion surgical suites used for lung restoration, another form of regenerative medicine. It turns donor lungs, which previously would have previously been unusable, into viable transplant organs. United Therapeutics also collaborates with Mayo Clinic on lung restoration.

The third floor houses the Life Sciences Incubator for biotech entrepreneurs, which offers coworking space, wet labs, business resources, networking and entrepreneurial training.

Read more:
United Therapeutics Receives Permit For Cell Therapy Facility Build-Out At Mayo - Pharmaceutical Online

Orthopedic surgeon and hand specialist Dr. Scott Zimmer will talk issues experienced with arthritis and ways to stop arthritis pain in an event titled, Arthritis: From the Fingertip to the Shoulder, the Latest Innovations in Arthritis Treatment, 6 p.m. Oct. 30 at 25501 Chagrin Boulevard in Beachwood.

Zimmer will discuss what arthritis is, how it affects the joints, methods to control arthritis pain at home, nonsurgical methods of easing pain if home methods stop working, including regenerative medicine and surgical methods.

Zimmer is the founder of Ohio Hand to Shoulder Center and a member of the Lake Health physician group. He also serves as department chair of hand and upper extremity surgery and vice president of medical staff at Lake Beachwood Medical Center. He previously directed the hand and upper extremity center for UH Geauga Medical Center for 10 years.

Light refreshments will be served.

Space is limited. To RSVP, call 800-454-9800 or visit tinyurl.com/Drzimmertalk.

Read the original here:
Dr. Scott Zimmer to speak about arthritis - Cleveland Jewish News

Stem cell therapy for animals has seen breakthroughs

Stem cell therapy is increasingly becoming a more mainstream form of medicine. Usually applied to humans, the use of this regenerative treatment is now also being extended to animals including cats and dogs. Regenerative medicine, particularly stem cell treatment has seen many advancements in recent years with some groundbreaking studies coming to light.

Taking the cells from bone marrow, umbilical cords, blood or fat, stem cells can grow to become any kind of cell and the treatment has seen many successes in animals. The regenerative therapy has been useful particularly for treatment of spinal cord and bone injuries as well as problems with tendons, ligaments and joints.

Expanded Potential Stem Cells (EPSCs) have been obtained from pig embryos for the first time. The cells offer groundbreaking potential for studying embryonic development and producing transnational research in genomics and regenerative medicine, biotechnology and agriculture.

The cells have been efficiently derived from pig preimplantation embryos and a new culture medium developed in Hong Kong and Cambridge enabled researchers from the FLI to establish permanent embryonic stem cell lines. The cells have been discovered in a collaboration between research groups from the Institute of Farm Animal Genetics at the Friedrich-Loeffler-Institut (FLI) in Mariensee, Germany, the Wellcome Trust Sanger Institute in Cambridge, UK and the University of Hong Kong, Li Ka Shing Faculty of Medicine, School of Biomedical Sciences.

Embryonic stem cells (ESC) are derived from the inner cells of very early embryos, the so-called blastocysts. Embryonic stem cells are all-rounders and can develop into various cell types of the body in the culture dish. This characteristic is called pluripotency. Previous attempts to establish pluripotent embryonic stem cell lines from farm animals such as pigs or cattle have resulted in cell lines that have not really fulfilled all properties of pluripotency and were therefore called ES-like.

Dr Monika Nowak-Imialek of the FLI said: Our porcine EPSCs isolated from pig embryos are the first well-characterized cell lines worldwide. EPSCs great potential to develop into any type of cell provides important implications for developmental biology, regenerative medicine, organ transplantation, disease modelling and screening for drugs.

The stem cells can renew themselves meaning they can be kept in culture indefinitely, and also show the typical morphology and gene expression patterns of embryonic stem cells. Somatic cells have a limited lifespan, so these new stem cells are much better suited for long selection processes. It has been shown that these porcine stem cell lines can easily be modified with new genome editing techniques such as CRISPR/Cas, which is particularly interesting for the generation of porcine disease models.

The EPSCs have a high capacity to develop not only into numerous cell types of the organism, but also into extraembryonic tissue, the trophoblasts, making them very unique and lending them their name. This capacity could prove valuable for the future promising organoid technology, where organ-like small cell aggregations are grown in 3D aggregates that can be used for research into early embryo development, various disease models and testing of new drugs in petri dishes. In addition, the authors were able to show that trophoblast stem cells can be generated from their porcine stem cells, offering a unique possibility to investigate functions or diseases of the placenta in vitro.

A major hurdle to using neural stem cells derived from genetically different donors to replace damaged or destroyed tissues, such as in a spinal cord injury, has been the persistent rejection of the introduced material (cells), necessitating the use of complex drugs and techniques to suppress the hosts immune response.

Earlier this year, an international team led by scientists at University of California San Diego School of Medicine successfully grafted induced pluripotent stem cell (iPSC)-derived neural precursor cells back into the spinal cords of genetically identical adult pigs with no immunosuppression efforts. The grafted cells survived long-term, displayed differentiated functionality and caused no tumours.

The researchers also demonstrated that the same cells showed similar long-term survival in adult pigs with different genetic backgrounds after only short course use of immunosuppressive treatment once injected into injured spinal cord.

Senior author of the paper Martin Marsala, MD, professor in the Department of Anesthesiology at UC San Diego School of Medicine said: The promise of iPSCs is huge, but so too have been the challenges. In this study, weve demonstrated an alternate approach.

We took skin cells from an adult pig, an animal species with strong similarities to humans in spinal cord and central nervous system anatomy and function, reprogrammed them back to stem cells, then induced them to become neural precursor cells (NPCs), destined to become nerve cells. Because they are syngeneic genetically identical with the cell-graft recipient pig they are immunologically compatible. They grow and differentiate with no immunosuppression required.

Co-author Samuel Pfaff, PhD, professor and Howard Hughes Medical Institute Investigator at Salk Institute for Biological Studies, said: Using RNA sequencing and innovative bioinformatic methods to deconvolute the RNAs species-of-origin, the research team demonstrated that pig iPSC-derived neural precursors safely acquire the genetic characteristics of mature CNS tissue even after transplantation into rat brains.

NPCs were grafted into the spinal cords of syngeneic non-injured pigs with no immunosuppression finding that the cells survived and differentiated into neurons and supporting glial cells at all observed time points. The grafted neurons were detected functioning seven months after transplantation.

Then researchers grafted NPCs into genetically dissimilar pigs with chronic spinal cord injuries, followed by a transient four-week regimen of immunosuppression drugs again finding long-term cell survival and maturation.

Marsala continued: Our current experiments are focusing on generation and testing of clinical grade human iPSCs, which is the ultimate source of cells to be used in future clinical trials for treatment of spinal cord and central nervous system injuries in a syngeneic or allogeneic setting.

Because long-term post-grafting periods between one and two years are required to achieve a full grafted cells-induced treatment effect, the elimination of immunosuppressive treatment will substantially increase our chances in achieving more robust functional improvement in spinal trauma patients receiving iPSC-derived NPCs.

In our current clinical cell-replacement trials, immunosuppression is required to achieve the survival of allogeneic cell grafts. The elimination of immunosuppression requirement by using syngeneic cell grafts would represent a major step forward said co-author Joseph Ciacci, MD, a neurosurgeon at UC San Diego Health and professor of surgery at UC San Diego School of Medicine.

Other recent advancements include the advancement toward having a long-lasting repair caulk for blood vessels. A new method has been for generating endothelial cells, which make up the lining of blood vessels, from human induced pluripotent stem cells. When endothelial cells are surrounded by a supportive gel and implanted into mice with damaged blood vessels, they become part of the animals blood vessels, surviving for more than 10 months.

The research was carried out by stem cell researchers at Emory University School of Medicine and could form the basis of a treatment for peripheral artery disease, derived from a patients own cells.

Young-sup Yoon, MD, PhD, who led the team, said: We tried several different gels before finding the best one. This is the part that is my dream come true: the endothelial cells are really contributing to endogenous vessels.

When cells are implanted on their own, many of them die quickly, and the main therapeutic benefits are from growth factors they secrete. When these endothelial cells are delivered in a gel, they are protected. It takes several weeks for most of them to migrate to vessels and incorporate into them.

Other groups had done this type of thing before, but the main point is that all of the culture components we used would be compatible with clinical applications.

This research is particularly successful as previous attempts to achieve the same effect elsewhere had implanted cells lasting only a few days to weeks, using mostly adult stem cells, such as mesenchymal stem cells or endothelial progenitor cells. The scientists also designed a gel to mimic the supportive effects of the extracellular matrix. When encapsulated by the gel, cells could survive oxidative stress inflicted by hydrogen peroxide that killed unprotected cells. The gel is biodegradable, disappearing over the course of several weeks.

The scientists tested the effects of the encapsulated cells by injecting them into mice with hindlimb ischemia (restricted blood flow in the leg), a model of peripheral artery disease.

After 4 weeks, the density of blood vessels was highest in mice implanted with gel-encapsulated endothelial cells. The mice were nude, meaning genetically immunodeficient, facilitating acceptance of human cells.

The scientists found that implanted cells produce pro-angiogenic and vasculogenic growth factors. In addition, protection by the gel augmented and prolonged the cells ability to contribute directly to blood vessels. To visualise the implanted cells, they were labelled beforehand with a red dye, while functioning blood vessels were labelled by infusing a green dye into living animals. Implanted cells incorporated into vessels, with the highest degree of incorporation occurring at 10 months.

Continue reading here:
Stem cell therapy is for animals too - SciTech Europa

Regenerative Medicine Market: Snapshot

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Order Brochure for more Detailed Information @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Request TOC for Facts & Tables @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Avail the Discount on this Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1889

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

Excerpt from:
Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities - Health News Office

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that it will be presenting at the Dawson James Securities 5th Annual Small Cap Growth Conference, being held on October 28-29, 2019 at the Wyndham Grand Hotel in Jupiter, Florida.

Preetam Shah, PhD, MBA, Chief Financial Officer is scheduled to present on Tuesday, October 29th at 3:40 p.m. Eastern Time, in Track 2 - Preserve Ballroom B, with one-on-one meetings to be held throughout the conference.

Chaim Lebovits, President and CEO of BrainStorm said, We are pleased to have the opportunity to have Dr. Shah present at the Dawson James Small Cap Growth Conference. Dr. Shah, joined BrainStorm in September 2019, and we look forward to having him present the Companys growth strategy and future to a wide audience of accreditied investors.

About NurOwn NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

AboutBrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website.

Safe-Harbor Statements Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PR Phone: +1.646.677.1839sean.leous@icrinc.com

Follow this link:
BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference - GlobeNewswire

Cotton candy is a staple of every carnival.Since 1904, children and adults alike have been entranced by the unique spinning process that conjures upbig sugar clouds seemingly out of nowhere.

Scientists are now using this concept to improve lab-grown meat in its mouthfeel and taste to better resemblemeat.

The technique researchers at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) are using is known as immersion Rotary Jet-Spinning (iRJS). It uses centrifugal force to spin long nanofibers of specific shapes and sizes much like when making cotton candy.

Thus far, they have grown rabbit and cow muscles on edible gelatin scaffolds that resemble the texture and consistency of meat, illustrating that realistic meat products may be an eventuality, sans the need to rear and butcher animals.

All this began after Kit Parker, the Tarr Family Professor of Bioengineering and Applied Physics at SEAS and senior author of the study, was a competition show judge on the Food Network.

"The materials science expertise of the chefs was impressive," said Parker. "After discussions with them, I began to wonder if we could apply all that we knew about regenerative medicine to the design of synthetic foods. After all, everything we have learned about building organs and tissues for regenerative medicine applies to food: healthy cells and healthy scaffolds are the building substrates, the design rules are the same, and the goals are the same: human health. This is our first effort to bring hardcore engineering design and scalable manufacturing to the creation of food."

The hardest thing about bioengineering meat is reproducing the skeletal muscle and fat tissue characteristic of animal meat, which grow in long, thin fibers -- as seen in the grain of a steak or the strings that come apart when shredding pork or chicken.

"Muscle cells are adherent cell types, meaning they need something to hold onto as they grow," said Luke Macqueen, first author of the study and postdoctoral fellow at SEAS and the Wyss Institute for Bioinspired Engineering. "To grow muscle tissues that resembled meat, we needed to find a 'scaffold' material that was edible and allowed muscle cells to attach and grow in 3D. It was important to find an efficient way to produce large amounts of these scaffolds to justify their potential use in food production."

The lab-grown meat has beenmechanically tested for comparisonalongside real rabbit, bacon, beef tenderloin, prosciutto and other meat products. Although their goal may not be as simple as spinning cotton candy, the researchers have shown that fully lab-grown meat is a possibility.

(This article was edited to correct somefactual errors)

Read the rest here:
The Key To Improving Lab-Grown Meat: Cotton Candy - International Business Times